HeartSciences Inc. (HSCS)
| Market Cap | 5.86M +43.5% |
| Revenue (ttm) | 8,669 -76.6% |
| Net Income | -8.49M |
| EPS | -4.03 |
| Shares Out | 3.19M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 49,524 |
| Open | 1.860 |
| Previous Close | 1.840 |
| Day's Range | 1.800 - 1.940 |
| 52-Week Range | 1.630 - 6.470 |
| Beta | 1.97 |
| Analysts | Buy |
| Price Target | 10.00 (+443.48%) |
| Earnings Date | Jul 23, 2026 |
About HSCS
HeartSciences Inc., a medical technology company, focuses on applying AI-based technology to an ECG to expand and improve clinical usefulness. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction caused by heart disease and/or age-related cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same test; and MyoVist... [Read more]
Financial Performance
In fiscal year 2025, HeartSciences's revenue was $4,350, a decrease of -76.61% compared to the previous year's $18,600. Losses were -$8.77 million, 32.7% more than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for HSCS stock is "Buy." The 12-month stock price target is $10.0, which is an increase of 443.48% from the latest price.
News
HeartSciences granted European patent for heart-monitoring technology
HeartSciences (HSCS) announced that the European Patent Office has granted the company a patent titled “Electrocardiogram-Based Assessment of Diastolic Function.” The patent covers machine-learning mo...
European Patent Granted for ECG-Based Assessment of Diastolic Function, Expands HeartSciences' Patent Portfolio to More Than 45 Granted Patents
Patent covers machine-learning models that use ECG data to estimate echocardiogram parameters indicative of diastolic function Patent covers machine-learning models that use ECG data to estimate echoc...
HeartSciences Launches MyoVista Insights™ Version 1.3 with AI-ECG Algorithm Marketplace and First FDA-Cleared Algorithm
Bunkerhill Health's FDA-cleared ECG-EF algorithm for the detection of reduced ejection fraction becomes the first cleared AI-ECG algorithm available through MyoVista Insights, advancing HeartSciences'...
HeartSciences enters commercial agreement with North Shore Health
HeartSciences (HSCS) announced that it has entered into a commercial agreement with North Shore Health, a community hospital serving Cook County, Minnesota and the surrounding region, to deploy the My...
HeartSciences Signs Commercial Agreement with North Shore Health, the First Hospital Deployment from the Cibolo Health Network
Agreement follows Cibolo Health's endorsement of MyoVista Insights for its network of 127 independent hospitals and reflects continued commercial momentum for HeartSciences' ECG management platform Ag...
HeartSciences signs MyoVista commercial agreement with St. Vincent Health
HeartSciences (HSCS) announced that it has signed a commercial agreement with St. Vincent Health to deploy the MyoVista Insights platform.
HeartSciences Signs First SaaS Revenues Agreement following full launch of MyoVista Insights™
Agreement with St. Vincent Health marks HeartSciences' transition from early adopter installations to commercial SaaS deployments following the full launch of MyoVista Insights at the American College...
HeartSciences Reminds Its Shareholders to Submit Their Vote at the Upcoming April 30, 2026, Annual Shareholders Meeting
Southlake, TX, April 14, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”) a healthcare information technology (“HIT”) company focused on advancing e...
HeartSciences' MyoVista Insights™ Receives Epic Toolbox Designation for ECG Management System Category
Southlake, TX , March 25, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advanci...
HeartSciences to Present at Investor Summit Group Virtual Conference and Host Virtual One on One Investor Meetings
Southlake, TX, March 24, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancin...
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on March 19, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on March 17, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
Southlake, Texas, March 16, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advan...
HeartSciences Quarterly report: Q3 2026
HeartSciences has published its Q3 2026 quarterly earnings report on March 16, 2026.
HeartSciences Earnings release: Q3 2026
HeartSciences released its Q3 2026 earnings on March 16, 2026, summarizing the period's financial results.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on March 6, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences announces UWE adopted MyoVista Insights, MyoVista wavECG
HeartSciences (HSCS) announced that the University of the West of England, UWE, has adopted the Company’s MyoVista Insights platform and MyoVista wavECG device as its exclusive ECG technologies to est...
University of West England Adopts HeartSciences' MyoVista Insights™ Platform and MyoVista® wavECG™ Device to Establish ECG Education and Technology Reference Center
Southlake, TX, Feb. 05, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company advancing electroca...
HeartSciences MyoVista Insights selected by Cibolo Rural Health Networks
HeartSciences (HSCS) announced that Cibolo Rural Health Networks has selected MyoVista Insights as its endorsed ECG management platform for independent hospitals within its high-value networks. This c...
Cibolo Health Designates HeartSciences' MyoVista Insights™ as Endorsed ECG Management Platform for Network of 123 Independent Hospitals
Southlake, TX, Jan. 29, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing...
HeartSciences Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
Southlake, TX, Dec. 15, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electroc...
HeartSciences announces FDA 510(k) submission for MyoVista wavECG
HeartSciences (HSCS) submitted its MyoVista wavECG device to the U.S. Food and Drug Administration for 510(k) premarket clearance. The MyoVista wavECG device is designed to provide conventional ECG fu...
HeartSciences Announces FDA 510(k) Submission for MyoVista® wavECG™ Device
Southlake, TX, Dec. 15, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company advancing the use of...
HeartSciences Quarterly report: Q2 2026
HeartSciences has published its Q2 2026 quarterly earnings report on December 15, 2025.
HeartSciences Earnings release: Q2 2026
HeartSciences released its Q2 2026 earnings on December 15, 2025, summarizing the period's financial results.